that PModS stimulates c-fos mRNA synthesis, but has no effect on two other nuclear proteins c-jun and C/EBP. The protein c-fos is a protooncogene that is transiently stimulated by a variety of mitogens and differentiation factors (7). Time-course data show that c-fos mRNA levels increase within minutes after PModS treatment and subsequently decline to basal levels after 2 h. In contrast, PModS-induced increases in Tf mRNA do not occur until 2 h, then peak at approximately 12 h, and are maintained for up to 5 days in culture. Treatment of Sertoli cells with a c-fos antisense oligonucleotide partially suppresses PModS-enhanced Tf protein production (6). These data indicate that c-fos is involved as an immediate early gene in response to PModS. The current study was designed to analyze PModS activation of the c-fos promoter and relate this to the previous data on signal transduction and Sertoli cell differentiation. Activation of the Tf promoter was investigated as a downstream event involved in Sertoli cell differentiation.
Materials and Methods
Cell preparation and culture 2) The 2-kb upstream HindIII-Hind111 fragment in the 3-kb mTf promoter was ligated in the Hind111 site of -581-bp mTf-CAT to obtain the 2.6-kb mTf-CAT plasmid.
3) The -1.6-kb mTf CAT plasmid was derived from the -3.O-kb mTf CAT (no. 1 above) by digesting out the upstream -1.4-kb PstI fragment. 4) To prepare the upstream l-kb mTf-CAT (I-kb Tf-Tk-CAT), the 3-kb mTf plasmid was digested with HindIII-PstI. The I-kb fragment (1.6-2.6 kb) was then cloned into a I'BL-CAT2 plasmid. Constructs for each of the plasmids that did not contain the specific response element or promoter fragment (i.e. promoterless plasmid) were also generated.
In all cases, experiments were performed to examine the actions of various treatments on these promoterless plasmids.
As The wells were then scraped, and the buffer was collected in 1.5-ml microfuge tubes. Tubes were heated to 65 C for 10 min to inactivate endogenous acetylases and then spun at 12,000 X ,Q for 10 min at 4 C to remove cell debris. Gel mobility shift assay
Gel shift assays were performed with nuclear extracts of isolated Sertoli cells. The Sertoli cells were isolated as described above and cultured in 137-mm petri dishes (Falcon Plastics, Oxnard, CA). The cells were treated after 48 h in culture either FSH, PModS(S300), or 10% calf serum. After 72 h, the cells were scraped off the petri dishes and washed once with PBS. The nuclear extracts of these cells were then prepared as described by Guillou et al. (14) . The probes used in gel retardation assays were the SRE (5'-GGATGTCCATATTAGGACACATCTG-3') and the ETS-SRE element (SRE with 5'-CAGGAT sequence) of the c-fos promoter; the SIE (5'-CATITCCCGTAAATC-3') located 25 bp upstream of the c+s SRE (15) 
Results
To confirm that c-fos is involved at a molecular level in PModS stimulation of Tf, a CAT reporter gene construct containing -2.6 kb of the Tf gene promoter was transiently transfected into cultured Sertoli cells. Sertoli cells were isolated from 20-day-old rat testis and cultured under serumfree conditions unless otherwise stated. After transfection, the cells were left untreated (control) or were treated with FSH, a partially purified PModS preparation from a sizeexclusion column termed PModS(S300), a combination of PModS (S300) and the antisense c-jos oligonucleotide (S300+ANTI), or a combination of PModS(S300) and the sense c-fos oligonucleotide (S300+SENSE) for 48 h before analysis of the cell extracts for CAT activity. FSH, S300, and S300+SENSE activated the Tf CAT construct (Fig. 1) . A control promoterless plasmid (pCAT-basic) was slightly stimulated by PModS(S300) treatment. Treatment of the transfected cells with the antisense oligonucleotide inhibited PModS(S300)-induced CAT activity (Fig. 1) . These data confirm that c-fos is involved in PModS-stimulated Tf gene expression. elements of the c-jos promoter were generated, including the CRE, TRE, SIE, and SRE. A schematic representation of the locations of these elements within the c-fos promotor is shown in Fig. 2A . These constructs were transiently transfected into cultured Sertoli cells. After transfection, the cells were left untreated (control) or were treated with FSH, 10% calf serum, (Bul,cAMP, PModS(S3001, or more highly purified PModS preparations from the C4 reverse phase column termed PModS(C4) for 48 h. The CRE of the c-jos promoter was activated by both FSH and (Bu),cAMP 400% above the control level (P < 0.051, which demonstrated that the reporter construct can be activated (data not shown). Treatment with PModS(S300) did not increase CRE-CAT activity above the control level (Fig. 2Bl . Treatment of the c-fos TRE-transfected cells with FSH resulted in a 300% stimulation above the control level (P < 0.051, which demonstrated that this reporter construct can be activated (data not shown). Treatment of the transfected Sertoli cells with PModS(S300) does not stimulate the TRE construct (Fig. 28) . A SRE construct was used that included the 5'-flanking 5-bp ETS domain ETS-SRE sequence of the c-fos promoter. Activation of the c-fos SRE construct was accomplished by treatment with 10% calf serum as a positive control to demonstrate that the reporter construct can be activated (data not shown). Both PModS(S300) and PModS(C4) activated the SRE construct (Fig. 2B) . The SIE construct was also stimulated by PModS(S3001 and PModS(C4) (Fig. 2B) 2 . a, Schematic representation of the c-fos promoter and the locations of the CRE, SRE, SIE, and TRE in promotor-CAT constructs. The designation for the promoter constructs is listed at the left, and that for the plasmid used at the right. b, Regulation of the c-fos promoter constructs (CRE, TRE, SIE, and SRE) in Sertoli cells cultured in the absence (control) or presence of PModS(S300) (m) and PModS(C4) (@. Data are expressed as a percentage of the control and are presented as the mean t SEM from six different experiments performed in replicate. same or lesser degree as that containing either element alone. The entire 400-bp c-fos promoter construct was stimulated approximately 900% over the control level by PModS(S300) (data not shown). The control plasmids not containing a promoter were not influenced by any of the treatments (data not shown). Purified PModS had a similar action as the partially purified PModS(S300). This indicates that stimulation of c-fos expression by PModS is in part mediated through activation of the SRE and SIE.
To extend these observations, gel retardation/mobility shift assays were performed. Nuclear extracts were obtained from Sertoli cells cultured in the absence (control) or presence of PModS(S300) or 10% (vol/vol) calf serum as a positive control. A gel shift with an oligonucleotide to Ott-1 was used to check the quality of the nuclear extracts (Fig. 3) . All extracts resulted in a similar level of Ott-1 gel shift. To confirm that c-fos was induced, a gel shift with an AI'1 oligonucleotide was performed, because the c-fos-jun complex binds to the AI'1 site. Incubation of the labeled API oligonucleotide with nuclear extracts of Sertoli cells treated with PModS6300) or serum resulted in the formation of a DNA-protein complex with retarded mobility (i.e. gel shift). The observed gel shift was specific for Al?, because it could be effectively competed by unlabeled AI'1 (Fig. 3) . This confirms the induction of c-fos by both PModS(S300) and serum.
Activation of SRE of the c-fos promoter was also investigated with a gel mobility shift assay using a SRE oligonucleotide (Fig. 4A) . PModS(S300) induced a gel shift that was competed with excess unlabeled SRE. Serum was used as a positive control and also promoted a gel shift. To assess whether PModS may promote binding of a ternary complex, an ETS-SRE sequence was used in a gel shift. The ETS domain is a 5'-CAGGAT flanking sequence of the SRE that is needed for the binding of ETS oncogene-like proteins and is required for the formation of a ternary complex with the serum response factor (SRF) that binds to the SRE. PModS6300) promoted a distinct shift with the ETS-SRE that was not present in control nontreated cells or in serum-treated cells (Fig. 4Al . PModS(S300) promoted two distinct gel shifts, whereas serum promoted a diffuse shift below that of PModS(S300). These gel shifts were displaced with excess unlabeled oligonucleotide (data not shown). Therefore, PModS6300) induced protein binding to the SRE and ETS-SRE oligonucleotides. An alternate response element, located 25 bp upstream from the SRE, is the SIE, which is also responsive to serum. A SIE oligonucleotide gel shift demonstrated that PModS(S300) promotes a SIE gel shift (Fig. 48) . Again, serum was used as a positive control and promoted the anticipated gel shift. This SIE gel shift was specific and could be competed by excess unlabeled SIE oligonucleotide. Previously, a SIE gel shift has been shown to involve three shifts, termed A, 8, and C. PModS was found to promote all three forms, with A (lowest) being the predominant (Fig. 4B) . The gel shift data presented confirm the reporter gene experiments previously discussed. Therefore, PModS appears to act through the SRE and SIE to promote c-fos gene expression.
Tfpromoter analysis
To determine the location of response elements within the Tf promoter that are activated by treatment with PModS, four CAT constructs containing a 581-bp, 1.6-kb, 2.6-kb, or 3-kb upstream region of the Tf promoter were produced (Fig.  5A ). FSH treatment of cells transfected with any of the constructs, except the 2.6-to 1.6-kb Tf PBL-CAT2, termed I-kb Tf-Tk-CAT, stimulated CAT activity approximately 400% above control values, confirming that these constructs can be activated (data not shown; P < 0.01). PModS(S300) treatment induced activation of the -581-bp, -1.6-kb, and -3-kb Tf constructs (Fig. 58) to a similar extent. The -2.6-kb Tf construct was stimulated to a greater extent by PModS(S300) (Fig. 58) . Interestingly, the PModS(C4) preparation stimu- lated primarily the -2.6-kb Tf construct. This indicates that an enhancer-like activity involved in PModS stimulation of Tf production is located between -1.6 and -2.6 kb, and a repressor is located between -2.6 and -3 kb of the promoter. To extend these observations, the lOOO-bp region of the promoter between -1.6 and -2.6 kb was cloned into a Tk-CAT construct (PBL-CAT2; Fig. 5A ), termed lkb Tf-Tk-CAT. PModS was found to activate this construct, but had only a slight effect on the control plasmid not containing the I-kb Tf promoter (Fig. 6) . PModS(C4) had an action similar to that of the partially purified PModS(S300). The plasmid used contained a minimal thymidine kinase (Tk) promoter with a TATA box (Tk-CAT) that was required for PModS to activate this l-kb Tf construct. In the absence of a minimal promoter with a TATA box, a similar construct was not activated (data not shown). Therefore, the ability of PModS to activate the enhancer elements in this Tf promoter fragment does require a minimal promoter containing a TATA box. Although the region between 0 and -581 bp has been sequenced and mapped, little is currently known about the distal region of the Tf promoter. Therefore, the exact nature of these putative upstream regulatory elements is unknown. To initiate an examination of this region, the entire 2.5-kb fragment of the Tf promoter between -581 bp and -3 kb was digested with various restriction enzymes to generate 15 approximately 200-bp fragments. These fragments were used in gel mobility shift assays to identify potential PModS- responsive regions. Thirteen of these Tf promoter restriction fragments did not cause a gel shift under control or PModSstimulated conditions (data not shown). Two restriction fragments upstream of the mTf transcriptional start site located at -2.4 kb, designated SEI, and at -1.9 kb, designated SE2, did cause a gel shift after PModS stimulation (Fig. 7) . The location of these Sertoli elements (i.e. SE1 and SE2) on the Tf promoter is diagrammatically shown in Fig. 5A . To determine whether either SE1 or SE2 is a potential APl-binding site, a competition experiment was carried out with excess unlabeled AI'1 oligonucleotide. The unlabeled API was not able to displace the SE1 or SE2 complex. Therefore, the gel shift appears not to be due to a c-fos/jun-binding AI'1 site. The SE2 fragment was unable to form the DNA-protein complex with the nuclear extracts of Sertoli cells treated with serum (Fig. 7) . PModS(S300) caused a gel shift with both SE1 and SE2 that was competed with excess unlabeled oligonucleotide (Fig. 7) . Excess SE2 DNA fragment did not compete for the SE1 complex, nor did the SE1 compete for the SE2 complex. These two, apparently distinct, non-APl-containing regions of the Tf promoter appear to be influenced by PModS actions on Sertoli cells.
FIG. 7.
Gel mobility shift assay with 32P-radiolabeled SE1 and SE2 regions of the Tf promoter. Nuclear extracts from Sertoli cells cultured in the absence (C) or presence of PModS(S300) (P) or 10% calf serum (S) were used. The DNA-protein complexes were electrophoretically separated on 5% polyacrylamide gels, then dried and autoradiographed.
Incubations with excess unlabeled SEl, SE2, or APl are indicated. The data are representative of four different experiments.
Treatment
C p --To confirm that c-fos does not associate with the PModSinduced SE1 and SE2 gel shifts, an immunoblot with a c-fos antiserum of the gel shifts was performed (Fig. 8) . Although a gel shift was detected with both SE1 and SE2, c-fos was not detected in the DNA-protein complex (Fig. 8) . A positive control API gel shift did contain c-fos in its DNA-protein complex (Fig. 8) . These observations imply that c-fos regulates an intermediate transcription factor(s) that influences the Tf promoter at SE1 and SE2 (Fig. 9) .
Discussion
The ability of the antisense c-fos oligonucleotide to inhibit PModSinduced activation of the Tf promoter in Sertoli cells transfected with the -2.6-kb Tf-CAT reporter construct correlates with its ability to inhibit Tf protein secretion (6). These data demonstrated that c-fos is involved in PModS stimulation of Tf expression by cultured Sertoli cells. To further investigate the actions of PModS on a molecular level, the effects of PModS on both the c-fos and Tf promoters were examined.
c-Fos promoter analysis
The responses of Sertoli cells treated with PModS and transfected with the reporter constructs containing the different regulatory elements of the c-fos promoter correlated with previous data obtained on the pharmacology of PModS. Treatment of cultured Sertoli cells with PModS did not affect CAMP levels (4), nor was it able to stimulate the reporter construct with the CRE of the c-fos promoter. The inability of PModS(S300) treatment to activate the TRE supports the observation that PModS does not stimulate either calcium mobilization or phosphoinositide turnover (5), both markers of protein kinase C activation. The inability of PModS to influence the TRE and APl (i.e. FAP) site at -290 bp of the c-fos promoter supports previous findings that PModS actions do not involve calcium mobilization or protein kinase C activation (5). Only the SRE and SIE were stimulated by treatment with the PModS(S300) and the highly purified PModS(C4) preparations. Interestingly, the presence of both SRE and SIE was not additive; the effect was the same or lesser than that of either element alone. Therefore, the ability of PModS to induce c-fos expression appears to be through the activation of SRE and SIE.
The SRE is a 29-bp region within the c-fos promoter. A 67-kilodalton protein has been isolated that binds to the SRE, the SRF (18) Immunoblot of an APl, SEl, and SE2 gel mobility shift assay with a c-fos antiserum. Nuclear extracts from Sertoli cells cultured in the presence of PModS(S300) (P) or 10% calf serum (S) were used. The DNA-protein complexes were electrophoresed and separated on 5% polyacrylamide gels, then either dried and autoradiographed (Gel Shift) or electrophoretically blotted to polyvinylidene difluoride membrane and immunoblotted with the c-fos antiserum (Blot). The data are representative of two experiments. SRE requires its phosphorylation (19-21). The actions of PModS require tyrosine phosphorylation events (5). The DNA-binding domain of SRF is the region necessary for dimerization and interaction with other proteins to form ternary complexes (18). Because SRF is ubiquitously expressed, cell-specific activation of the c-fos SRE by SRF appears to be mediated by other ternary complex protein factors. The binding of the ternary complex to the SRE requires the presence of the adjoining 5'-side of the SRE-binding site, the ETS domain binding motif. The protein kinase C-dependent and -independent pathways target different parts of this ternary complex (22). The expression and/or phosphorylation of these proteins may be involved in mediating cellspecific responses by the SRE. The SRE gel shift data presented demonstrate that PModS induced a gel shift similar to that of the positive control with serum treatment. Under less stringent conditions, a SRE gel shift was detected in control cells, but a more abundant gel shift was present in PModS-treated Sertoli cells (data not shown). The identity of the PModS-induced SRE-binding protein as SRF or other binding proteins remains to be elucidated. Interestingly, PModS induced a unique gel shift with the ETS-SRE that was not observed in control nontreated cells or in serum-treated cells. Therefore, PModS appears to promote the binding of a protein complex (e.g. ternary complex) that activates the SRE within the c-fos promoter. The formation of these ternary complexes may enable a common regulatory element, such as the SRE, to have cell-specific activity using ubiquitously expressed DNA-binding proteins. Alternatively, different or unique binding factors may be another method by which a common regulatory element may differentially activate cellspecific gene expression. In support of this proposal, several A second regulatory element that appears to be involved in PModS stimulation of c-fos is the SIE. It is located 25 bp upstream of the SRE. The SIE is activated by binding of the SIF, which has three forms, A, B, and C, and contains a phosphotyrosine residue (11). Treatment of human epidermoid carcinoma cells with epidermal growth factor and human hepatoma cells with interleukind induces the binding of SIF-A, whereas treatment of epidermoid cells with interferon-y induced binding of SIF-C (11). This is also an example of the ability of different binding proteins to activate a common regulatory element and stimulate a gene-specific response. PModS induced a SIE gel shift that appears to involve predominantly SIFtA), but also had detectable SIF(B) and SIF(C) gel shifts. PModS was also found to activate a SIE reporter construct. Interestingly, the effects of both the SIE and SRE were not additive in response to PModS. PModS appears to influence the c-fos promoter at both the SRE and SIE. Whether the SIE can compensate and/or regulate the SRE response remains to be elucidated.
Tf promoter analysis
The downstream effects of PModS-induced c-fos expression were investigated with use of the Tf gene as a differentiated marker of Sertoli cells. The gene expression of Tf was inhibited by an antisense c-fos oligonucleotide, indicating that actions of PModS on the Tf promoter are indeed a downstream c-fos event. The regions controlling liver-specific transcription of the human Tf gene are composed of multiple positive and negative acting elements, mostly interacting with DNA-binding proteins present in either human or rat liver nuclear extracts (26, 27) . The regulation of Tf gene expression in unstimulated Sertoli cells has been shown to be distinct from that of liver gene expression (28). Although the first 581 bp of the human Tf promoter (hTf) and mTf promoter have little similarity, they both contain a CRE site,
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OF SERTOLI DIFFERENTIATION 3053 which was found to be responsive to FSH in the current study. The results with the CAT-mTf deletion mutants suggest that an enhancer activity is located between -2.6 and -1.6 kb for PModS and a repressor between -2.6 and -3.0 kb. Analysis of restriction enzyme fragments of the Tf promoter between -581 bp and -3kb identified two distinct domains, designated SE1 and SE2, that bind specific nuclear proteins from Sertoli cells stimulated with PModS. Interestingly, these Sertoli response elements (i.e. SE1 and SE2) are located within the apparent enhancer activity between -2.6 and -1.6 kb of the Tf promoter.
Treatment with serum also induced a similar DNA-protein complex with SEl. The complex formed with SE2 was specific to PModS(S300), because treatment with serum or CAMP (data not shown) could not induce the gel shift. The lack of competition of SE1 and SE2 with AI'1 suggested that these sites were independent of APl and the binding of a c-fos-jun complex. The c-fos immunoblot confirmed the absence of c-fos in the SE1 and SE2 DNAprotein complexes.
Therefore, PModS induced Tf gene expression may involve both c-fos-dependent and -independent response elements. Future studies will involve elucidation of the precise mechanism by which PModS activates the SRE and SIE of the c-fos promoter and Sertoli cell-specific response elements (e.g. SE1 and SE2) of the Tf promoter.
The possibility that Sertoli cell-specific trans-acting factors and ternary complex factors as well as unique response elements may be involved in the Sertoli cell-specific activation of these promoters is being investigated.
